Consilient Health announce the re-launch of Mysimba

/in , /by

Consilient Health are pleased to announce the re-launch of Mysimba, a prescription medicine which can help your patients achieve their weight loss goals.

Mysimba  is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of;

  • ≥ 30 kg/m2 (obese), or
  • ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co- morbidities e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension. 

Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight.

Guidelines suggest the use of MYSIMBA in patients with overweight or obesity with emotional eating.1

Consider MYSIMBA for your patients with emotional eating as due to its mode of action in the brain it is designed to help to control hunger and cravings. 1, 2

Support tools including a Mode of Action Video, Patient Information Booklet, Physician Prescribing Checklist and Dose Card are available on Mysimba.ie.

Click here to view the Mysimba SPC on medicines.ie.

Consilient Health can be contacted at  irishoffice@consilienthealth.com or drugsafety@consilienthealth.com.

 

References:

  1. Chianelli et al, Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment, Journal of Endocrinological Investigation, 2023, www.medicines.ie.
  2. Acosta et al, Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic, Obesity (2021) 29, 662-671.

 

MYS-0364-001 10/24
IE-CH-1634
Date of Preparation: October 2024